365 related articles for article (PubMed ID: 29703869)
21. Clinical features and prognostic factors in severe cutaneous drug reactions.
Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
[TBL] [Abstract][Full Text] [Related]
22. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
23. HLA-B*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia.
Low DE; Nurul-Aain AF; Tan WC; Tang JJ; Bakhtiar MF; Murad S; Chang CC; Too CL; Tang MM
Pharmacogenet Genomics; 2020 Sep; 30(7):153-160. PubMed ID: 32433341
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
[TBL] [Abstract][Full Text] [Related]
25. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
26. A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea.
Kang DY; Yun J; Lee SY; Koh YI; Sim DW; Kim S; Nam YH; Park JW; Kim SH; Ye YM; Park HK; Kim MH; Jee YK; Jung JW; Yang MS; Kim SH; Lee JK; Kim CW; Hur GY; Kim MY; Park SJ; Kwon YE; Choi JH; Kim JH; Kim SH; La HO; Kang MG; Park CS; Lee SM; Jeong YY; Kim HK; Jin HJ; Jeong JW; Lee J; Lee YW; Lee SE; Kim MS; Kang HR;
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):929-936.e7. PubMed ID: 32961314
[TBL] [Abstract][Full Text] [Related]
27. Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients.
Na Bangxang P; Wisuthsarewong W; Nitiyarom R
Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183639
[TBL] [Abstract][Full Text] [Related]
28. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.
Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C
J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132
[TBL] [Abstract][Full Text] [Related]
29.
Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
[TBL] [Abstract][Full Text] [Related]
30. Severe cutaneous adverse reactions in a tertiary care center in Jamaica.
McNish AJS; Ho JD; East-Innis ADC
JAAD Int; 2024 Jun; 15():139-146. PubMed ID: 38545494
[TBL] [Abstract][Full Text] [Related]
31. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
32. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling in allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
van Nguyen D; Chu HC; Vidal C; Anderson J; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Fulton RB; van Nunen S; Fernando S
Pharmacogenomics; 2020 Sep; 21(14):985-994. PubMed ID: 32896208
[No Abstract] [Full Text] [Related]
34. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
35. An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital.
Lekshmipriya K; Pradeesh A; Vasudevan B; Dash M; Sood A; Gera V
Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S209-S216. PubMed ID: 38144617
[TBL] [Abstract][Full Text] [Related]
36. Recurrence of drug-induced reactions in DRESS patients.
Picard D; Vellar M; Janela B; Roussel A; Joly P; Musette P
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):801-4. PubMed ID: 24628777
[TBL] [Abstract][Full Text] [Related]
37. Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase®.
Shukla S; Rastogi S; Abdi SAH; Dhamija P; Kumar V; Kalaiselvan V; Medhi B
Seizure; 2021 Oct; 91():332-338. PubMed ID: 34274893
[TBL] [Abstract][Full Text] [Related]
38. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan.
Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177
[TBL] [Abstract][Full Text] [Related]
40. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea.
Yang MS; Kim JY; Kang MG; Lee SY; Jung JW; Cho SH; Min KU; Kang HR
Korean J Intern Med; 2019 Jan; 34(1):195-201. PubMed ID: 29466850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
